Mendelian Randomization Provides No Evidence for a Causal Role of Serum Urate in Increasing Serum Triglyceride Levels
Overview
Genetics
Affiliations
Background: Triglycerides and their lipoprotein transport molecules are risk factors for heart disease. Observational studies have associated elevated levels of serum urate (SU) with triglycerides and risk of heart disease. However, owing to unmeasured confounding, observational studies do not provide insight into the causal relationship between SU and triglyceride. The aim of this study was to test for a causal role of SU in increasing triglyceride using Mendelian randomization that accounts for unmeasured confounding.
Methods And Results: Subjects were of European ancestry from the atherosclerosis risk in communities (n=5237) and Framingham heart (n=2971) studies. Mendelian randomization by the 2-stage least squares regression method was done with SU as the exposure, a uric acid transporter genetic risk score as instrumental variable, and triglyceride as the outcome. In ordinary linear regression, SU was significantly associated with triglyceride levels (β=2.69 mmol/L change in triglyceride per mmol/L increase in SU). However, Mendelian randomization-based estimation showed no evidence for a direct causal association of SU with triglyceride concentration-there was a nonsignificant 1.01 mmol/L decrease in triglyceride per mmol/L increase in SU attributable to the genetic risk score (P=0.21). The reverse analysis using a triglyceride genetic risk score provided evidence of a causal role for triglyceride in raising urate in men (P(Corrected)=0.018).
Conclusions: These data provide no evidence for a causal role for SU in raising triglyceride levels, consistent with a previous Mendelian randomization report of no association between SU and ischemic heart disease.
Liang N, Yuan X, Zhang L, Shen X, Zhong S, Li L Life Metab. 2025; 3(5):loae018.
PMID: 39872146 PMC: 11749550. DOI: 10.1093/lifemeta/loae018.
Huang Y, Li Y, Wu Z, Liang Y, He J Lipids Health Dis. 2024; 23(1):363.
PMID: 39511685 PMC: 11542235. DOI: 10.1186/s12944-024-02346-z.
Managing Gout in Patients with Metabolic Syndrome.
Ebstein E, Ottaviani S Drugs Aging. 2024; 41(8):653-663.
PMID: 39060816 DOI: 10.1007/s40266-024-01132-x.
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies.
Leask M, Crisan T, Ji A, Matsuo H, Kottgen A, Merriman T Nat Rev Rheumatol. 2024; 20(8):510-523.
PMID: 38992217 DOI: 10.1038/s41584-024-01137-1.
Choi H, Kwon B, Kwon M, Kim J, Kim J, Park B J Pers Med. 2022; 12(4).
PMID: 35455721 PMC: 9032264. DOI: 10.3390/jpm12040605.